September I 2025

A novel combination therapy shows promising results in metastatic colorectal cancer, offering improved response rates and survival compared to existing treatments.

New trial results reveal sacituzumab govitecan shows significant antitumor activity in recurrent cervical cancer, especially in heavily pretreated patients.

A phase 1 trial of BA3182 shows promising safety and antitumor activity in treatment-refractory adenocarcinoma patients, highlighting its potential.

KIM-1 emerges as a promising biomarker for renal cell carcinoma, enhancing prognosis and treatment decisions in kidney cancer management.

Belzutifan shows improved quality-adjusted survival in advanced renal cell carcinoma compared with everolimus, enhancing patient quality of life and treatment outcomes.

Combination therapy of casdatifan and cabozantinib shows promising efficacy and manageable safety in patients with advanced clear cell renal cell carcinoma.

Researchers explore the impact of CD163-positive tumor-associated macrophages on the effectiveness of nivolumab in treating metastatic clear cell renal cell carcinoma.

Pembrolizumab and lenvatinib show promising survival rates and durable responses in advanced non-clear cell renal cell carcinoma, transforming treatment standards.

Recent advances in treating Philadelphia chromosome-positive acute lymphoblastic leukemia offer hope for long-term remission without transplant, highlighting TKI discontinuation's potential.

Discover how AI transforms practice management by streamlining documentation, enhancing patient experiences, and optimizing workflows for healthcare professionals.

Recent advancements in multiple myeloma treatment highlight the promise of trispecific antibodies like JNJ-5322, potentially enhancing patient outcomes significantly.

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data from recent clinical trials.